Abstract
Because local recurrence is common after a curative resection for advanced gastric cancer, there has been significant interest in adjuvant chemotherapy. However, the overall effect of chemotherapy remains debatable regarding patients with advanced gastric adenocarcinoma. Multidrug resistance is thought to be a major cause of failure in cancer chemotherapy, and thus the expression of P-glycoprotein (P-Gp), multidrug resistance-associated protein (MRP), and lung-resistance protein (LRP) in tumor cells was evaluated by immunohistochemistry. In 20 gastric adenocarcinomas, 11 (55%), 2 (10%), and 0 (0%) were positive for MRP, LRP, and P-Gp. In malignant lymphomas, only 3 out of 10 cases were positive for MRP (30%). The positive rate of MRP staining was significantly higher in well and moderately differentiated adenocarcinomas (80%) than in poorly differentiated adenocarcinomas (20%). With regard to the degree of MRP expression and histological cell type, higher grades (grade 2–3) were observed only in well and moderately differentiated adenocarcinomas. In terms of the positive-stained cells and staining intensity, heterogeneity was observed in the staining profile of MRP. The proliferative cell nuclear antigen labeling index (PCNA LI) of MRP-positive and MRP-negative cases was 49.3%±11.6% and 49.4±6.9%, respectively. No correlation was observed between the MRP expression and PCNA LI. In conclusion, the incidence of MRP expression in gastric cancer was the highest in three different multidrug resistance-related epitopes. An evaluation of the MRP expression thus seemed to be beneficial for determining the optimal strategy of chemotherapy.
Similar content being viewed by others
References
Charles SF (1997) Chemotherapy for advanced gastric cancer: where do we stand? J Clin Oncol 15:3299–3300
Charles SF, Robert JM (1995) Gastric carcinoma. N Engl J Med 333:32–41
Cunningham D (1988) Gastric cancer. The recognition of a chemosensitive tumour. Br J Cancer 58:695–699
Neri B, de Leonardis V, Romano S, Andreoli F, Pernice LM, Bruno L, Borrelli D, Valeri A, Fabbroni S, Intini C, Cini G (1996) Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. Br J Cancer 73:549–552
Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, van de Velde (1993) Adjuvant therapy after curative resection for gastric cancer: Meta-analysis of randomized trials. J Clin Oncol 11:1441–1447
Douglass HO Jr (1989) Gastric cancer. Current status of adjuvant therapy. Oncology 3:61–66
Allum WH, Hallissey MT, Ward LC, Hockey MS (1989) A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. Br J Cancer 60:739–744
Coombes RC, Schein PS, Chilvers CE, Wils J, Beretta G, Bliss JM, Rutten A, Amadori D, Cortes-Funes H, Villar-Grimdt A (1990) A randomized trial comparing adjuvant fluorouracil, doxorubicin and mitomycin with no treatment in operable gastric cancer. International collaborative cancer group. J Clin Oncol 8:1362–1369
Lise M, Nitti D, Marchet A, Sahmoud T, Buyse M, Duex N, Fiorentino M, Dos Santos JG, Labianca R, Rougier P, Gignoux M (1995) Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol 13:2757–2763
Bleiberg H, Gerard B, Deguiral P (1992) Adjuvant therapy in resectable gastric cancer. Br J Cancer 66:987–991
Pastan I, Gottesman M (1987) Multiple drug resistance in human cancer. N Engl J Med 316:1388–1393
Endicott JA, Ling V (1989) The biochemistry of P-glycoprotein mediated multidrug resistance. Annu Rev Biochem 58:137–171
Kaye SB (1988) The multidrug resistance phenotype. Br J Cancer 58:691–694
Cornwell MM, Tsuruo T, Gottesman MM, Pastan I (1987) ATP-binding properties of P-glycoprotein from multidrug resistant KB cells. FASEB J 1:51–54
Gottesman MM, Pastan I (1988) The multidrug transporter, a double-edged sword. J Biol Chem 263:12163–12166
Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265–269
Scheper RJ, Broxterman HJ, Scheffer GL, Meijer CJLM, Pinedo HM (1992) Drug-transporter proteins in clinical multidrug resistance. Clin Chim Acta 206:25–32
Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP, Deeley RG (1994) Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54:357–361
Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650–1654
Krishnamachary N, Center MS (1993) The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-KDa membrane bound glycoprotein. Cancer Res 53:3658–3661
Schadendorf D, Makki A, Stahr C, Van Dyck A, Wanner R, Scheffer GL, Flens MJ, Scheper R, Henz BM (1995) Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol 147:1545–1552
Zaman GJ, Flens MJ, van Leusden MR, de Haas M, Mulder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ, Borst P (1994) The human multidrug resistance-associated protein (MRP) is a plasma membrane drug efflux pump. Proc Natl Acad Sci USA 91:8822–8826
Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH, van Kalken CK, Slovak ML, de Vries EG, van der Valk P, Meijer CJ, Pinedo HM (1993) Overexpression of a Mr 110 000 vesicular protein in non-P-glycoprotein mediated multidrug-resistance. Cancer Res 53:1475–1479
Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ (1995) The drug resistance relatted protein LRP is the human major vault protein. Nat Med 1:578–582
Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Von Hoff DD, Roninson IB (1990) Quantitative analysis of MDR-1 (multi drug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87:7160–7164
Verrelle P, Meissonnier F, Feillel V, Djonet C, Kwiatkowski F, Plagne R, Chassagne J (1991) Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst 83:111–116
Hipfner DR, Gauldie SD, Deeley RG, Cole SP (1994) Detection of the Mr 190 000 multidrug resistance protein, MRP with monoclonal antibodies. Cancer Res 54:5788–5792
Flens MJ, Izquierdo MA, Scheffer GL, Fritz JM, Meijer CJ, Scheper RJ, Zaman GJ (1994) Immunochemical detection of the multidrug resistance associated protein MRP in human multidrug resistant tumor cells by monoclonal antibodies. Cancer Res 54:4557–4563
Yuen AR, Sikic BI (1994) Multidrug resistance in lymphomas. J Clin Oncol 12:2453–2459
Mizoguchi T, Yamada K, Furukawa T, Hidaka K, Hisatsugu T, Shimazu H, Tsuruo T, Sumizawa T, Akiyama S (1990) Expression of the MDR-1 gene in human gastric and colorectal carcinomas. J Natl Cancer Inst 82:1679–1683
Machara Y, Anai H, Kusumoto H, Sugimachi K (1987) Poorly differentiated human gastric carcinoma is more sensitive to antitumor drugs than well differentiated carcinoma. Eur J Surg Oncol 13:203–206
Endo K, Maehara Y, Ishiyoshi Y, Kusumoto T, Sakaguchi Y, Ohno S, Sugimachi K (1996) Multidrug resistance-associated protein expression in clinical gastric carcinoma. Cancer 77:1681–1687
Izquierdo MA, van der Zee AG, Vermorken JB, van der Valk P, Belien JA, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM, Kenemans P, Meijer CJ, de Vries EG, Scheper RJ (1995) Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 87:1230–1237
Ota E, Abe Y, Oshika Y, Ozeki Y, Iwasaki M, Inoue H, Yamazaki H, Ueyama Y, Takagi K, Ogata T, Tamaoki N, Nakamura M (1995) Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer. Br J Cancer 72:550–554
Jain S, Filipe MI, Hall PA, Waseem N, Lane DP, Levison DA (1991) Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol 44:655–659
Shen DW, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I, Gottesman MM (1986) Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science 232:643–645
Kakehi Y, Kanamaru H, Yoshida O, Ohkubo H, Nakanishi S, Gottesman MM, Pastan I (1988) Measurement of multidrug-resistance messenger RNA in urogenital cancers; elevated expression in renal cell carcinoma is associated with intrinsic drug resistance. J Urol 139:862–865
Slovak ML, Ho JP, Bhardwaj G, Kurz EU, Deeley RG, Cole SP (1993) Localization of a novel multidrug resistance-associated gene in the HT 1080/DR4 and H69AR human tumor cell lines. Cancer Res 53:3221–3225
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Alexander, D., Yamamoto, T., Kato, S. et al. Histopathological assessment of multidrug resistance in gastric cancer: Expression of P-glycoprotein, multidrug resistance-associated protein, and lung-resistance protein. Surg Today 29, 401–406 (1999). https://doi.org/10.1007/BF02483030
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02483030